Pacs Group Stock Earnings Reports

PACS Group reported a strong start to 2026 driven by operational consistency, improving facility integration, and continued clinical performance. The company operated 323 facilities (approx. 35,500 beds) and served roughly 31,900 patients daily at quarter-end. Key operational takeaways include high occupancy (90.9% overall; mature facilities at 94.8%), improving skilled mix (30.5% company-wide; 33% at mature facilities), and clinical quality gains (222 facilities rated 4 or 5 stars). Financial results were robust: Q1 revenue of $1.42 billion (+11% y/y), net income of $80.7 million, adjusted EBITDA of $170.4 million (+75% y/y) and diluted EPS of $0.50. Adjusted EBITDA benefited from $16.3 million of California quality incentive payments; management excludes future quality payments from guidance due to timing uncertainty. Balance sheet remains conservative with ~$800 million liquidity (including ~$250 million cash) and net leverage of ~0.1x. The Board approved a $250 million share repurchase authorization for opportunistic buybacks. Management increased full-year adjusted EBITDA guidance to $605–$625 million (a $50 million raise across the range) while reaffirming revenue guidance of $5.65–$5.75 billion and will no longer bake future acquisitions into guidance. M&A pipeline remains active with selective, disciplined pursuit; management also highlighted continued options to increase real estate ownership. Leadership transition: Carey Hendrickson named CFO, Mark Hancock retiring to become Vice Chairman. The company continues to cooperate with ongoing government investigations and is progressing remediation of previously disclosed internal control weaknesses.